Pharma

Biogen BIIB

BIOGEN INC.Biological Products, (No Diagnostic Substances)DE

Pipeline — registered trials by phase

A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

— · Relapsing Forms of Multiple Sclerosis · Not Yet Recruiting · est. 2034-07-28

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

— · Major Depressive Disorder · Completed · est. 2019-09-24

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)

— · Relapsing Multiple Sclerosis · Completed · est. 2015-10

A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

— · Major Depressive Disorder · Completed · est. 2023-06-22

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

— · Spinal Muscular Atrophy · Completed · est. 2017-02-20

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)

— · Amyotrophic Lateral Sclerosis · Completed · est. 2021-07-16

Long-Term Evaluation of BIIB067 (Tofersen)

— · ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation · Completed · est. 2024-08-12

Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency

— · Renal Insufficiency, Congestive Heart Failure · Completed · est. 2009-10-30

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a

— · Relapsing Multiple Sclerosis · Completed · est. 2015-10

A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)

— · Spinal Muscular Atrophy · Active Not Recruiting · est. 2027-09-24

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

— · Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis · Completed · est. 2017-04-24

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

— · Primary Membranous Nephropathy · Recruiting · est. 2030-01-28

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

— · Relapsing-Remitting Multiple Sclerosis · Completed · est. 2016-01

Natalizumab Re-Initiation of Dosing

— · Multiple Sclerosis, Relapsing-Remitting · Completed · est. 2007-12

Source: ClinicalTrials.gov (trials where Biogen is lead sponsor; 76 active or completed) and Drugs@FDA (6 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.

SEC filings — insider trading forms excluded

SCHEDULE 13G/A2026-08-06SCHEDULE 13G/A
10-Q2026-07-29Quarterly report
8-K2026-07-29Current report (material event)
8-K2026-07-01Current report (material event)
8-K2026-06-10Current report (material event)
8-K/A2026-06-10Current report (amended)
SCHEDULE 13G/A2026-06-05SCHEDULE 13G/A
SCHEDULE 13D/A2026-05-14SCHEDULE 13D/A
8-K2026-05-14Current report (material event)
SC TO-T/A2026-05-14SC TO-T/A
SC TO-T/A2026-05-12SC TO-T/A
SC TO-T/A2026-05-06SC TO-T/A
SCHEDULE 13G/A2026-05-06SCHEDULE 13G/A
SCHEDULE 13G2026-04-29SCHEDULE 13G
10-Q2026-04-29Quarterly report
8-K2026-04-29Current report (material event)
ARS2026-04-28Annual report to holders
DEFA14A2026-04-28DEFA14A
DEF 14A2026-04-28Proxy statement
SC TO-T2026-04-14SC TO-T
SC TO-C2026-04-07SC TO-C
SCHEDULE 13D2026-04-06SCHEDULE 13D
8-K2026-04-06Current report (material event)
SC TO-C2026-04-03SC TO-C
SC TO-C2026-03-31SC TO-C
8-K2026-03-31Current report (material event)
SC TO-C2026-03-31SC TO-C
SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
8-K2026-03-11Current report (material event)
8-K2026-02-11Current report (material event)
10-K2026-02-06Annual report
8-K2026-02-06Current report (material event)
SCHEDULE 13G2026-02-05SCHEDULE 13G
8-K2026-01-14Current report (material event)
SCHEDULE 13G/A2025-11-13SCHEDULE 13G/A
SCHEDULE 13G2025-11-10SCHEDULE 13G
10-Q2025-10-30Quarterly report
8-K2025-10-30Current report (material event)
8-K2025-10-14Current report (material event)
8-K2025-07-31Current report (material event)

Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.